Processing your request

please wait...

Case Page


Case Status:    ONGOING    
On or around 10/13/2020 (Date of last review)

Filing Date: January 23, 2017

According to the law firm press release, on August 14, 2014, Mallinckrodt acquired Questcor Pharmaceuticals, Inc. ("Questcor") in a $5.6 billion transaction. As a result of the acquisition, Mallinckrodt added HP Acthar Gel ("Acthar"), an injectable medication made from pigs' pituitary glands, to its drug portfolio. Acthar is the only approved therapeutic preparation of adrenocorticotropic hormone ("ACTH") in the U.S., and is approved by the U.S. Food and Drug Administration ("FDA") as a treatment for 19 different conditions, including infantile spasms, and difficult-to-treat autoimmune and inflammatory conditions. Given the monopoly status of Acthar in the U.S. market, Questcor, and later Mallinckrodt, repeatedly increased the price of Acthar 85,000% from $40 per vial in 2001 to over $34,000 per vial in 2017.

The complaint alleges that, throughout the Class Period, Mallinckrodt and its Chief Executive Officer ("CEO") made a series of false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of the Company's monopolistic Acthar revenues and the exposure of Acthar to reimbursement rates by Medicare and Medicaid. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that Acthar's monopoly status as the only FDA-approved ACTH preparation was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that the Company's monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.

On March 9, 2018, the Court issued an Order appointing Lead Plaintiff and Counsel and consolidating related actions. Lead Plaintiff filed a consolidated Complaint on May 18. Defendants filed a Motion to Dismiss the consolidated Complaint on July 17.

One of the individual Defendants was voluntarily dismissed on August 30, 2018.

On July 30, 2019, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss.

On October 12, 2020, Mallinckrodt plc and its affiliated debtors commenced bankruptcy cases in the United States Bankruptcy Court for the District of Delaware. The Court stayed the case on October 13.


Sector: Healthcare
Industry: Major Drugs
Headquarters: United Kingdom


Ticker Symbol: MNK
Company Market: New York SE
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. District Columbia
DOCKET #: 17-CV-00145
JUDGE: Hon. Emmet G. Sullivan
DATE FILED: 01/23/2017
CLASS PERIOD END: 01/18/2017
  1. Kessler Topaz Meltzer & Check LLP (Pennsylvania)
No Document Title Filing Date
COURT: D. District Columbia
DOCKET #: 17-CV-00145
JUDGE: Hon. Emmet G. Sullivan
DATE FILED: 05/18/2018
CLASS PERIOD END: 11/06/2017
  1. Barrack, Rodos & Bacine (Main office, Philadelphia)
  2. Murray Murphy Moul + Basil LLP
No Document Title Filing Date
—Related District Court Filings Data is not available